FcRn Inhibition for the Treatment of Generalized Myasthenia Gravis (gMG): Patient Selection, Tailoring Dosing Regimens, Updated Disease Management Paradigms

FcRn Inhibition for the Treatment of Generalized Myasthenia Gravis (gMG): Patient Selection, Tailoring Dosing Regimens, Updated Disease Management Paradigms is organized by AcademicCME.

Description:
Compared to traditional immunomodulatory therapies, new biologic therapeutics for gMG have more specific target engagement via blockade of immunoglobulin G recycling via the neonatal Fc receptor (FcRn; such as efgartigimod, rozanolixizumab) or inhibition of complement activation (such as eculizumab, ravulizumab, zilucoplan). Phase 3 trials with each of these agents have shown rapid clinical improvement and good safety and tolerability. As a result, a paradigm shift away from nonspecifically targeted therapies is upon us.  It is early in this new era to compare outcomes with FcRn inhibition vs complement inhibition, but at present, the former is in much broader clinical use owing largely to economic considerations by payors. This current state of affairs warrants education of HCPs who provide care to patients with gMG on the data supporting the use of FcRn blockers, longer-term outcomes with these agents, patient selection, dose management, and—while we await guidelines updates--on a reconsideration of the sequencing of therapeutic options for the management of gMG.

Learning Objectives:

• Understand the mechanism of action of FcRn blockers AChR-Ab+ gMG and review foundational clinical trial data
• Analyze recent secondary analyses of clinical trials and reported experience with incorporation of FcRn blockers into gMG management
• Review recently reported safety experience and patient selection processes for incorporation of FcRn blockers into gMG management
• Plan implementation of therapy with appropriate selection of patients for individualized management of generalized MG by the interprofessional team at the host center